Physician profile
Travis Webster
NPI 1245970730
$502.39
in general payments reported to CMS, 2019-2025
11 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $289 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $164.08 | 2024-2025 | Mounjaro, Zepbound |
| Ucb, INC. | $70.13 | 2024-2025 | Briviact, Fintepla |
| Exact Sciences Corporation | $63.48 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $46.00 | 2024-2025 | Evenity, Otezla, Prolia |
| Paratek Pharmaceuticals, INC. | $31.25 | 2025 | Nuzyra |
| Lexicon Pharmaceuticals, INC. | $31.04 | 2024 | |
| Phathom Pharmaceuticals, INC. | $23.11 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $22.16 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.99 | 2025 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $16.98 | 2024 | Terlivaz |
| Esperion Therapeutics, INC. | $15.17 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.